CONTEMPORARY REVIEW

Sex-Specific Considerations in Degenerative Aortic Stenosis for Female-Tailored Transfemoral Aortic Valve Implantation Management

Giulia Masiero, MD; Valeria Paradis, MD; Anna Franzone, MD; Barbara Bellini, MD; Chiara De Biase, MD; Nicole Karam, MD; Francesca Sanguineti, MD; Mamas A. Mamas, MD; Hélène Eltchaninoff, MD; Chiara Fraccaro, MD; Battistina Castigioni, MD; Tiziana Attisano, MD; Giovanni Esposito, MD; Alaide Chieffo, MD

ABSTRACT: The impact of sex on pathophysiological processes, clinical presentation, treatment options, as well as outcomes of degenerative aortic stenosis remain poorly understood. Female patients are well represented in transfemoral aortic valve implantation (TAVI) trials and appear to derive favorable outcomes with TAVI. However, higher incidences of major bleeding, vascular complications, and stroke have been reported in women following TAVI. The anatomical characteristics and pathophysiological features of aortic stenosis in women might guide a tailored planning of the percutaneous approach. We highlight whether a sex-based TAVI management strategy might impact on clinical outcomes. This review aimed to evaluate the impact of sex from diagnosis to treatment of degenerative aortic stenosis, discussing the latest evidence on epidemiology, pathophysiology, clinical presentation, therapeutic options, and outcomes. Furthermore, we focused on technical sex-oriented considerations in TAVI including the preprocedural screening, device selection, implantation strategy, and postprocedural management.

Key Words: aortic stenosis ■ clinical management ■ device selection ■ sex differences ■ transcatheter aortic valve implantation

Degenerative aortic stenosis (AS) currently represents one of the most frequent nonrheumatic valvular heart diseases worldwide.1 Nevertheless, the impact of sex on pathophysiology, clinical presentation, and outcomes in AS remains poorly defined.2 Female patients are well represented in the transcatheter treatment of severe AS, both in national registries and landmark trials, and several lines of evidence suggest that women might experience greater benefit than men with transfemoral aortic valve implantation (TAVI) compared with surgical treatment.3–7 In this review, we aimed to describe the impact of female sex on diagnosis and management of severe AS, discussing the latest evidence on epidemiology, pathophysiology, presentation, and treatment. The novelty of this review is its focus on technical sex-oriented considerations ranging from preprocedural screening to periprocedural tricks and postprocedural management, including the latest technological innovations. Moreover, we aimed to report whether sex-based TAVI management protocols might impact on clinical outcomes.

IMPACT OF FEMALE SEX IN THE DIAGNOSIS OF ACQUIRED AS

Epidemiology, Pathophysiology, and Natural History

The prevalence of symptomatic severe AS is up to 4% in elderly patients (aged >75 years), with equal frequency in both sexes.
Nonstandard Abbreviations and Acronyms

| Abbreviation | Description |
|--------------|-------------|
| AS           | aortic stenosis |
| MDCT         | multidetector computed tomography |
| TAVI         | transfemoral aortic valve implantation |
| THV          | transcatheter heart valve |

in men and women and a mortality rate of over 50% at 2 years of follow-up unless promptly treated. The main cause of acquired AS involves a degenerative age-related valve mineralization, a dynamic process with lipid accumulation, chronic inflammation, and active valve leaflet calcification. However, little is known about the role of sex in the progression of valve disease and in the ventricular response to the pressure overload (Figure 1). In contrast to men, who develop a fibrotic dilated cardiomyopathy, left ventricular ejection fraction (LVEF) is less likely to deteriorate in women who experience a relatively greater wall thicknesses but smaller left ventricular (LV) cavities because of concentric hypertrophy. This remodeling process reverses more often in women shortly after aortic valve replacement. The pathological explanation for such different remodeling patterns and the extent of ventricular fibrosis partly relies on a lower expression of proinflammatory and inflammatory genes (eg, collagen I–II, matrix metalloproteinase 2, transforming growth factor-β signaling pathways), which have been found in the interstitial cells of intraoperative myocardial biopsy specimens. Differences in valve morphology have also been described, because female sex is associated with a lower degree of aortic valve calcification measured by multidetector computed tomography (MDCT) in patients with a similar degree of hemodynamic stenosis severity evaluated at Doppler echocardiography, even after adjustment for body surface area (BSA) and echocardiographic parameters. The histological detection of higher levels of valvular fibrosis and dense connective tissue might explain why in women a more fibrotic aortic valve remodeling is observed for a given aortic stenosis severity. In contrast, male patients have histological evidence of more pronounced calcific valve remodeling irrespective of patients’ age. Conflicting data exist on the natural progression of AS according to sex. Some data suggest similar progression of aortic valve disease in men and women with respect to the gradient, velocity, or valve area; whereas other studies have reported that female sex is an independent predictor of mean aortic valve gradient progression, showing a significant association with AS-related event rates at long-term follow-up.

Diagnostic Assessment

Consistent sex-specific guideline criteria for the grading of disease severity are still lacking. Echocardiographic assessment warrants indexed values for BSA (aortic valve area index, <0.6 cm²/m²), but the same correction has not been applied for other hemodynamic parameters such as mean gradient or peak velocity. Transthoracic echocardiographic evaluation is often challenging, because it may underestimate the LV outflow tract area and stroke volume, resulting in discrepancies between mean gradient and aortic valve area index. In addition, up to 40% of patients present with a severe reduction of calculated aortic valve area index with low-gradient AS. The classical low-flow–low gradient because of low LVEF is more prevalent in men, whereas a paradoxical low flow–low gradient disease, where LVEF is preserved but stroke volume index is <35 mL/m², is more common in elderly women because of their small, restrictive LV cavity, greater arterial stiffness, and higher ventricle-arterial impedance. This process may be found in 10% to 15% of the AS population and may lead to paradoxical underestimation of the severity of the disease, leading to undertreatment of female patients. Although the transthoracic echocardiogram remains the standard diagnostic test, MDCT could provide more detailed quantification of AS severity and progression, using the true MDCT measured LV outflow tract area for reclassification of aortic valve area and calculation of the aortic valve calcium load that is strongly associated with worse morbidity and mortality. Women require lower levels of aortic valve calcium load to reach hemodynamically severe AS compared with men, with sex-specific calcium scores for the diagnosis of AS. Thresholds for severe AS assessed by means of computed tomography measurement of aortic valve calcification (Agatston units) are: men>3000, women>1600=likely; men>2000, women>1200=likely; men<1600, women<800=unlikely. Interestingly, this discordant calcific/fibrotic patterns between men and women may be
exacerbated in specific valve morphology such as stenotic bicuspid valve that shows less aortic valve calcification for the same hemodynamic severity not only in men but also compared with women with severe tricuspid aortic valve stenosis. Lastly, cardiac magnetic resonance could provide complementary information on LV function, because it allows identification of different patterns of hypertrophy and remodeling and quantifies the extent of LV fibrosis in late gadolinium enhancement assessment. However, data on cardiac magnetic resonance evaluation of sex differences in myocardial LV fibrosis are still limited. Nevertheless, the sex differences in the pathophysiological process and clinical presentation of severe AS might further benefit from an integrated diagnostic approach to avoid late referral and adverse outcomes encountered in female patients.

**IMPACT OF FEMALE SEX IN THE TREATMENT OF AS**

**Current Guidelines Recommendations and the Role of the Heart Team**

Historically, female patients with AS have been turned down for surgical aortic valve replacement more often than men, mainly because of their late presentation and perceived greater risk of perioperative complications. The introduction of TAVI flattened the sex-related gap in the treatment of AS; women represent >50% of patients undergoing TAVI. Nevertheless, although female sex is a known risk factor for perioperative mortality in both the EuroSCORE and the Society of Thoracic Surgeons risk score, current international guidelines do not provide sex-specific recommendations on treatment. The heart team plays a pivotal role in the selection of the optimal modality of intervention (surgical or transcatheter) for each individual patient, based on clinical, anatomical, and procedural features. Factors favoring the choice of TAVI over surgical aortic valve replacement in female patients include advanced age at presentation, greater frailty, lower prevalence of concomitant severe coronary artery disease, and higher likelihood of patient–prosthesis mismatching smaller aortic annulus.

**TAVI in Female Patients: Summary of Clinical Outcomes**

Current data around TAVI outcomes in female patients compared with male patients are derived from subanalyses of randomized trials and observational studies (Table 1). Among comparative studies, in the combined cohorts of the PARTNER (Placement of Aortic

---

**Table 1.** Epidemiological, pathophysiological, and diagnostic peculiarities in female patients affected by degenerative AS.

| **Epidemiology**                  | **Prevalence of severe AS**                  |
|----------------------------------|---------------------------------------------|
|                                  | Up to 4% between elderly patients (>75 years) |
|                                  | ≥ frequency in men and women                 |
| **Natural progression**          | Conflicting results on disease progression |
|                                  | High rate of asymptomatic severe AS but greater symptomatic burden |
|                                  | Lower prevalence of comorbidities            |

| **Pathophysiology**              | **Patterns of AV remodeling**                |
|---------------------------------|---------------------------------------------|
|                                  | ↓ extent of AV load but comparable degree of valvular stenosis |
|                                  | ↑ levels of valvular fibrosis and dense connective tissue |

| **Pathophysiology**              | **Patterns of LV hypertrophy**               |
|---------------------------------|---------------------------------------------|
|                                  | ↓ extent of ventricular fibrosis (↓ expression of pro-fibrotic and inflammatory genes) |
|                                  | ↑ concentric hypertrophy                     |
|                                  | ↑ wall thicknesses and LVEF                  |
|                                  | ↓ LV cavities                                |

| **Diagnostic assessment**        | **Echocardiography**                         |
|---------------------------------|---------------------------------------------|
|                                  | LV concentric remodelling                   |
|                                  | ↑ paradoxical LF-LG AS                      |

| **Diagnostic assessment**        | **MDCT**                                    |
|---------------------------------|---------------------------------------------|
|                                  | Smaller anatomic root                       |
|                                  | Lower coronary take off                     |
|                                  | ↓ AVC threshold for severe AS               |
|                                  | Smaller ilio-femoral vessels and BSA        |

| **Diagnostic assessment**        | **cMR**                                     |
|---------------------------------|---------------------------------------------|
|                                  | ↓ LV mass index                             |
|                                  | ↑ myocardial fibrosis                        |

AS indicates aortic stenosis; AV, aortic valve; AVC, aortic valve calcification; BSA, body surface area; cMR, cardiac magnetic resonance; LF-LG, low flow–low gradient; LV, left ventricular; LVEF, left ventricular ejection fraction; and MDCT, multidetector computed tomography.
Table 1. Studies Comparing the Main Clinical Outcomes After Transcatheter Aortic Valve Implantation in Female and Male Patients

| Study or first author and design | Overall population, n | % Women | Follow-up | Mean age, y | Operative risk, % | Vascular complications | Bleeding | All-cause mortality |
|----------------------------------|-----------------------|---------|-----------|-------------|------------------|------------------------|---------|-------------------|
|                                  |                       |         | Women     | Men         | Women Men       | Women Men             | Women   | Men               |
| FRANCE 2 registry, prospective   | 39'2                  | 49.5    | 1 y       | 84.0±6.6   | 81±6.5          | 21.4±13*               | 4.6     | 1.9               |
| observational                    |                       |         |           |             |                 |                        | 4.3     | 1.9               |
| Kodali et al, analysis of RCT     | 2559                  | 47.6    | 30 d      | 84.9±6.9   | 84.1±7.3        | 11.9±4.2               | 17.3    | 5.08              |
| Szerlip et al, analysis of RCT1   | 1661                  | 39.5    | 1 y       | 82.5±7.2   | 82.0±7.1        | 6.8±3.0                | 7.2     | 4.2               |
| Sannino et al, retrospective      | 910                   | 46.5    | 1 y       | 82.0±7.6   | 80.9±8.4        | 7.9±3.7                | 7.1±4.0 | 7.8               |
| observational                    |                       |         |           |             |                 |                        | 4.1     | 4.0               |
| Doshi et al, retrospective        | 41'050                | 47.7    | In-hospital| 81.7±8.1   | 80.5±9.1        | 7.9±3.7                | 3.9     | 3.3               |
| observational1                    |                       |         |           |             |                 |                        | 28.3    | 20                |
| Stehle et al, prospective         | 683                   | 58      | 30 d      | 84.2±5.2   | 83.2±6.9        | 5.2±3.1                | 4.6±3.5 | 8.2               |
| observational                     |                       |         |           |             |                 |                        | 5.6     | 3.3               |
| FRAILTY-AV, prospective           | 759                   | 44.8    | 1 y       | 84.2±5.3   | 82.8±5.8        | 6.5±3.8                | 5.8±4.4 | ...               |
| observational1                    |                       |         |           |             |                 |                        | ...     | ...               |
| TVT registry, prospective         | 23'662                | 49.9    | 1 y       | 82.3±8.5   | 81.7±8.6        | 9±6                    | 8.3     | 4.4               |
| observational1                    |                       |         |           |             |                 |                        | 8.0     | 5.9               |
| Forrest et al, analysis of RCT1   | 36'87                 | 46.3    | 1 y       | 84.0±7.6   | 82.7±7.9        | 9.6±4.9                | 8.3±4.6 | 9.7               |
| D'Ascenzo et al, retrospective     | 377                   | 57.2    | 30 d      | 82.9±5.4   | 81.6±5.3        | 5.6±3.1                | 7.6±6.2 | 12.9              |
| observational1                    |                       |         |           |             |                 |                        | 9.8     | 24                |
| Humphries et al, analysis of RCT1 | 659                   | 55.8    | 1 y       | 82±5       | 80±7            | 23±14*                 | 23±14*  | 2.2               |
| Czarnecki et al, retrospective     | 641                   | 51.3    | 30 d      | 83         | 82              | 7.5                    | 7.5     | 12.4              |
| observational1                    |                       |         |           |             |                 |                        | 12.4    | 5.4               |
| Katz et al, prospective           | 999                   | 45.3    | 1 y       | 85         | 83              | 7.0±5.0*               | 8.0±7.0*| 18.7              |
| observational1                    |                       |         |           |             |                 |                        | 16.7    | 14.5              |
| Tarantini et al, prospective      | 819                   | 51      | 30 d      | 82.4±7.0   | 80.6±7.5        | 15.4±13                | 11.4±9.5| 11.2              |
| observational1                    |                       |         |           |             |                 |                        | 5.5     | 7.4               |
|                                 | 1694                  | 49      | 30 d      | 82.7±6.3   | 80.8±6.9        | 17.9±1.7*              | 17.8±13.9*| 3.7               |
|                                 |                       |         |           |             |                 |                        | 2.7     | ...               |
|                                 |                       |         |           |             |                 |                        | ...     | 36†               |
|                                 |                       |         |           |             |                 |                        | 39.7†   |                   |

FRAILTY-AVR indicates Frailty Aortic Valve Replacement study; FRANCE 2, FRench Aortic National CoreValve and Edwards 2 registry; RCT, randomized control trial; TAVI, transcatheter aortic valve implantation; and TVT, Transcatheter Valve Therapy registry.

*Logistic EuroScore; all the other risk scores are reported as Society of Thoracic Surgeons risk score.

†4-year results.
Transcatheter Valves) II SAPIEN 3 (S3) (Edwards Lifesciences) trial, which included high- and intermediate-risk patients, female sex was independently associated with an increased risk of major vascular complications, but no differences in 30-day survival or stroke rate were observed in women compared with men.4 In the Society of Thoracic Surgeons/American College of Cardiology Transcatheter Valve Therapy registry, vascular complications were more frequent among 11,808 women compared with 11,844 men (8% versus 4%; adjusted hazard ratio [HR], 1.7 [95% CI, 1.3–2.1]; P<0.001), whereas mortality at 1 year was lower (21% versus 25%, adjusted HR, 0.7 [95% CI, 0.6–0.9]; P<0.001).32 Likewise, in 2 large meta-analyses, women experienced higher rates of major vascular complications, major bleeding events, and stroke than men.26,38 A low BSA and smaller peripheral vessel diameter increases the risk of bleeding and vascular complications in the periprocedural phase. In this context, device innovation has the potential to mitigate the burden of access-site complications in women undergoing TAVI through a progressive reduction of the size and profile of delivery systems and the extended use of expandable sheaths.39 On the other hand, female sex was associated with a survival advantage at long-term follow-up (mean follow-up length of 3.3±1.1 years).29 A lower prevalence of comorbidities in addition to the longer life expectancy enjoyed by women compared with men in the general population may drive the higher survival reported in the longer term. Conversely, an analysis of a contemporary cohort of patients treated with the SAPIEN 3 (Edwards Lifesciences, Irvine, CA) or Corevalve Evolut R or Evolut Pro (Medtronic, Minneapolis, MN) valves found similar rates of in-hospital mortality, stroke, and pacemaker implantation in women and men.40

The WIN TAVI (Women’s International Transcatheter Aortic Valve Implantation) registry was the first international, multicenter, prospective observational registry of 1019 female patients undergoing TAVI at 18 European and 1 North American center between 2013 and 2015. Baseline clinical characteristics included a mean age of 83 years and mean LVEF of 56%; ≈90% of patients were considered at high risk for surgery. Transfemoral TAVI was performed in 91% of cases, with 42% use of second-generation valves. At 30-days, the primary VARC-2 (Valve Academic Research Consortium 2) early safety end point (composite of mortality, stroke, major vascular complications, life-threatening bleeding, stage 2 or 3 acute kidney injury, coronary artery obstruction, or repeat procedure for valve-related dysfunction) occurred in 14% and was mainly driven by vascular complications (7.7%) or bleeding events (4.4%). Increasing age, history of stroke, LVEF <30%,
and first-generation devices were found independent predictors of the primary end point. At 1 year, a primary efficacy composite end point (including mortality, stroke, myocardial infarction, hospitalization for valve-related symptoms or heart failure or valve-related dysfunction) occurred in 167 (16.5%) patients, with nearly half of the rates previously reported in studies including first-generation devices; rates of all-cause mortality and stroke were 13% and 2%, respectively. No associations between history of pregnancy and 1-year outcomes were observed.

Additional evidence is expected with the results of the RHEIA (Randomized Research in Women All Comers With Aortic Stenosis) trial, a prospective, randomized multicenter study that tests noninferiority and, eventually, the superiority of TAVI versus surgical aortic valve replacement for a primary end point composed of all-cause mortality, all stroke, and rehospitalization for valve or procedure-related symptoms or worsening congestive heart failure at 1 year after the procedure among >400 women with severe aortic stenosis (NCT04160130).

**PROPOSED SEX-ORIENTED TAVI MANAGEMENT**

The distinctive anatomical characteristics and pathophysiological features of AS in women affect outcomes after TAVI and should guide tailored TAVI planning, procedural strategy, and postprocedural management (Figure 2). Several measures and technical tricks can be implemented during standard TAVI planning and the procedure to minimize adverse events in a sex-oriented approach, taking into account the longer life expectancy of female patients. All the proposed recommendations are integrated into a contemporary lean TAVI clinical pathway.

**Preprocedural Screening and Device Selection**

Currently, preprocedural screening of a patient candidate to TAVI is the same for women and men and consists of a multimodality imaging evaluation including transthoracic echocardiography, coronary angiography, MDCT, according to institutional protocols. Among them, the gold standard imaging modality is MDCT, which can also play a role in screening for coronary artery disease. As previously highlighted, women present more often with a small anatomic root (including small annulus, sinus of Valsalva, and sinotubular junction), low coronary ostia, and small iliofemoral vessels resulting in an unfavorable sheath-to-femoral artery ratio, together with a small BSA. Accordingly, careful measurement of these parameters should be performed and compared with the anatomical requirements for the different available transcatheter heart valves (THVs) and their respective sizing charts to select the most appropriate THVs and vascular access in a patient-tailored fashion.

First of all, it is well noted that currently available THVs cover different specific ranges of annulus size, with SAPIEN (Edwards Lifesciences), Corevalve Evolut...
(Medtronic), Portico (Abbott Structural Heart, Santa Clara, CA), Allegra (New Valve Technology, Hechingen, Germany), and Myval (Meril Life Sciences, Gujarat, India) as those who are approved for the small annulus size (<20mm). To date, there are no randomized trial data with regard to the superiority of one device to others in the case of a small annulus size. The SMART (Small Annuli Randomized to Evolut or SAPIEN) trial, comparing the 2 most widely available contemporary TAVI devices, the Medtronic Evolut PRO/PRO+ self-expanding and the Edwards SAPIEN 3/SAPIEN 3 Ultra balloon-expandable devices in aortic valve annulus area of ≤430 mm², is still ongoing. The SMART trial will be the largest trial to enroll primarily female patients.

Second, the presence of small annulus size (generally considered as an annulus size <23mm), one of the predictors of patient–prosthesis mismatch even after THV implantation, should be taken into account for device selection. Patient–prosthesis mismatch after TAVI may be associated with less regression of LV hypertrophy, LV diastolic dysfunction, LV filling pressure, less improvement in LV systolic function, and less reduction of left atrial volume. However, clinical data to demonstrate the impact of patient–prosthesis mismatch on long-term outcomes after TAVI are not available yet. In practice, one may argue that, in case of a small annulus size, it is worthwhile to pursue the largest effective orifice area and the lowest trans-valvular gradient through the use of a self-expandable supra-annular device. However, the sealing skirts of supra-annular devices are particularly high, and especially in the case of associated small sinotubular junction, may hamper selective coronary artery cannulation (Figure 3).

Finally, the delivery sheath profile must be obviously considered in the choice of the most appropriate THV. As discussed above, in case of suboptimal vascular access (small sheath-to-femoral artery ratio, higher tortuosity, and diffuse and circumferential calcification), a device with a low-profile delivery system has to be selected. The CoreValve Evolut R and Pro+ (Medtronic) can be implanted using the InLine sheath with 14 Fr outer diameter equivalent (minimum vessel diameter requirements, 5.0mm for sizes 23, 26, 29mm, in the absence of circumferential calcification); also, the last generation low-profile delivery system FlexNav (Abbott Structural Heart, Santa Clara, CA) designed for the Portico and Navitor valve (Abbott Structural Heart), provides the same low insertion profile (access down to 5.0-mm vessels). Other devices require at least 5.5-mm minimum vessel diameter or larger. If transfemoral access is not feasible, the heart team can consider different peripheral vascular approaches such as trans-subclavian/transaxillary (both CoreValve and Portico iterations have a Conformité Européenne mark of approval for this vascular approach).

Implantation Strategy and Periprocedural Considerations in Female Patients

Risk of Vascular and Access-Related Complications

Because female sex seems to be independently associated with an almost double risk of vascular complications after TAVI, with a relative risk of 1.6 compared with men, it is mandatory to adopt every possible technique to minimize this risk as per Figure 4:

1. Use of 2-dimensional ultrasound guidance during access site vascular puncture, because it has been associated with a significant reduction in the rate of major vascular complications and major bleeding over conventional fluoroscopic guidance.
2. In case of heavy, circumferential calcifications, additional tools should help to increase patient eligibility and reduce vascular complications (ie, percutaneous transluminal angioplasty, paving and cracking endovascular techniques, debulking devices). Among them, intravascular lithotripsy is a recent promising technique in which ultrasound disrupts intimal and medial calcification, altering vessel compliance to allow for the safe passage of large-bore delivery sheaths. This expands the patient cohort that could be eligible for transfemoral access, which still remains the first choice whenever possible and is associated with decreased morbidity and mortality compared with nontransfemoral access. However, alternative routes may be considered (transsubclavian, transcarotid, transapical, transaortic, transcaval) in case of an unfeasible transfemoral route.
3. A minimalistic approach with a radial access to guide valve implantation or manage peripheral vascular complications and an over-the-wire rapid pacing reduce the secondary access site failures. In case the secondary artery access is the contralateral femoral artery, the prepositioning of a crossover guidewire may help in the management of any vascular complication should it occur.
4. The hemostasis technique is of utmost importance. A balloon inflation advanced from contralateral femoral artery to create a dry field during final hemostasis may be helpful for managing TAVI vascular access sites. Most importantly, different sutured-based and collagen plug-based vascular closure devices are now available. The use of 2 Perclose Proglide (Abbott Vascular, Santa Clara, CA) devices was associated with a lower rate of major or minor vascular complications and lower rates of acute kidney injury in patients undergoing transfemoral TAVI in comparison to Prostar XL (Abbott Vascular). Moreover, the plug-based Manta device (Teleflex, Wayne, PA), specifically designed for large-bore arteriotomy closure, recently showed reliable safety and
efficacy in selected TAVI populations. Further registry data suggested that it was associated with faster hemostasis and a lower rate of vascular complications compared with the suture-based strategy, whereas early randomized studies highlighted a higher than anticipated rate of Manta-access vascular events (up to 19%).\(^{66,67}\) It remains to be determined whether inherent differences in the design and operation of those devices may guide a sex-tailored choice.

5. The optimal management of antithrombotic therapy during the periprocedural phase may significantly impact on the rate of vascular complications. In particular, considering the frequent low body weight of female patients, it is recommended to administer a weight-based dose of unfractioned heparin with a close monitoring of activated clotting time. In line with the most recent scientific evidence and recommendations, dual antiplatelet therapy should be administered only in case of recent percutaneous coronary intervention.\(^{68}\)

**Risk of Left Ventricle Perforation**

A small left ventricle cavity and an hypercontractile state, frequently encountered in female patients with AS, together with a thin muscular wall and a narrow aorto-mitral angle, are potential predictors of the occurrence of left ventricle perforation during TAVI.\(^{69}\) Left ventricle perforation primarily occurs secondary to the valve delivery wire inadvertently being pushed too distally through the left ventricle apex in a small cavity, even if the operators perform an appropriate curve on the distal stiff end of the wire. It is suggested to use dedicated preshaped stiff wires with soft spiral tips to mitigate this risk. For example, the Amplatz Extra-Stiff APEX wire (Cook Medical) has a double curve design composed of a larger curve with the distal tip of the wire forming a 2-mm J bend; it can be easily maneuvered in smaller ventricles, whereas the Safari2TM wire is available in 3 different loop sizes, offering the possibility to select the curve size according to the size of the ventricle\(^ {70}\) (Figure 4).

**Risk of Acute Coronary Occlusion**

Female sex is one of the strongest baseline clinical factors associated with the risk of acute post-TAVI coronary occlusion, a rare but life-threatening complication; in several observational experiences focusing on coronary obstruction following TAVI, the vast majority (>80%) of patients were women.\(^ {71}\) Coronary obstruction following TAVI is mainly caused by the displacement of the calcified native leaflet over the coronary ostia in the presence of lower coronary ostia and/or narrow aortic root, leaving little room to accommodate the native aortic leaflets, and as previously

---

**Figure 4.** Periprocedural TAVI considerations to address the specific issues associated with the treatment of female patients.

LV indicates left ventricle; PPM, patient–prosthesis mismatch; SFAR, sheath-to-femoral artery ratio; TAVI, transcatheter aortic valve implantation; and THV, transcatheter heart valve.
described, these are frequent anatomical features in female patients. Moreover, in patients with prior surgical or percutaneous aortic valve treatment undergoing valve-in-valve or TAVI-in-TAVI procedures, the risk of acute coronary occlusion, either directly or indirectly by sequestering the sinus of Valsalva at the sinotubular junction, is up to 6-fold higher compared with TAVI for native aortic valve disease. Many criteria for selecting patients at high risk for obstruction have been proposed, including native or bioprosthetic aortic leaflet length that extends above the coronary ostia or above the sinotubular junction, a coronary artery height ≤10 mm, a virtual valve to coronary artery/to sinotubular junction distance, respectively, of ≤4 and ≤2 mm, degenerative stentless bioprosthetic valve, or with externally mounted leaflets.

Along with a tailored THV choice considering future valve reintervention in a lifetime management strategy, several periprocedural measures are useful to mitigate the risk of acute coronary obstruction, such as (Figure 3 and 4):

1. Accurate MDCT preprocedural planning with virtual simulations of prostheses implantation (the usefulness of 3-dimensional printing models is under investigation in this field).
2. If pre-TAVI balloon valvuloplasty is required, simultaneous angiography to depict coronary patency or obstruction.
3. In case of the abovementioned clinical and anatomical parameters of risk, consider leaflet modification strategies (ie, BASILICA [Bioprosthetic or Native Aortic Scallop Intentional Laceration to Prevent Iatrogenic Coronary Artery Obstruction]) and/or different technical strategies for coronary patency protection (eg, guiding catheter placement, guidewire placement, prepositioned stent, ready to be deployed after TAVI in a chimney or snorkel fashion, or orthotopic stent strategy).
4. Use of self-expandable valves with a concave shape nitinol frame at the level of coronary arteries (with mandatory commissural alignment during implantation) rather than a balloon expandable straight cobalto-chromium frame.
5. Use of a repositionable/retrievable THV or a valve with different anchoring mechanism (paper clip–like anchorage mechanism at the level of the leaflets).
6. Avoid unnecessary oversizing.

**Risk of Paravalvular Leak and Aortic Annulus Rupture**

Again, in a small hypertrophic left ventricle, any pressure or volume residual overload can impact on symptoms relief and clinical outcome. Notwithstanding, female patients less frequently experience residual paravalvular leak; smaller annular size, greater use of TAVI oversizing, lower aortic valve calcification burden, and higher achieved true cover index typically found in female patients undergoing TAVI are likely contributing factors to this finding. Conversely, balloon-expandable TAVI oversizing ≥20% of the annular area is associated with an 8-fold increased risk of annulus rupture, and this is more frequently described in women than men.

1. It is generally recommended to optimize the procedural result by an accurate evaluation of valve hemodynamics in the catheterization laboratory (residual gradients and regurgitation). It is advisable to assess invasively any residual transprosthetic gradient.
2. Intra- or paravalvular leak has to be accurately detected by multimodality evaluation (including supraortic angiogram, intraprocedural echocardiogram evaluation, aortic and left ventricle invasive pressure measurements, aortic regurgitation index) to try to optimize the result by means of adjunctive maneuvers (ie, after dilatation). The use of the dicrotic notch index to assess for paravalvular leak avoiding left ventricle measurements is currently under investigation.

**Risk of Conduction Disorders and Permanent Pacemaker**

A left bundle-branch block and the dyssynchrony lead by pacing stimulation are badly tolerated in case of a small hypertrophic left ventricle.

1. A valve implant as high as possible may help to reduce the risk of conduction disorders (Figure 4).
2. If a pacemaker is needed, the most physiological stimulation modality should be pursued, and atrial contribution should be preserved whenever possible. Within this perspective, the measurement of membranous septum length by computed tomography scan can provide a patient-specific approach to device implantation depth, because implanting the device at a depth less than the membranous septum length helps to significantly reduce permanent pacemaker rate.

**Lifetime Management Strategy**

Considering the longer life expectancy of women, it is particularly advisable to tailor THV choice and implantation strategy to optimize valve performance and foresee the strategy of future valve reintervention (Figure 4). Different scenarios may arise:

1. In the case of a small sinus of Valsalva and narrow sinotubular junction, the priority should be...
to preserve the easiest coronary reaccess possible, with consideration of future valve-in-valve. Accordingly, in case of short-frame THV device selection, a slightly deeper implantation into the LV outflow tract can be attempted (for example, 60:40 instead of 70:30 or 80:20) to keep the neo-commissural plane below the coronary ostia plane. On the other hand, if a long-frame device is implanted, implantation strategies aiming to obtain commissural alignment should be implemented. In case of elderly patients with a larger BSA, a supra-annular device may be a good option, particularly when using commissural alignment strategies during implantation. On the other hand, in patients with known associated coronary artery disease and/or longer life expectancy (entailing an increased risk of further procedures of TAVI-in-TAVI or percutaneous coronary intervention), a balloon expandable intra-annular short frame device could be preferred, especially if implanted in a subcoronary position.

The enrolling SMART trial may help to address this issue.

**POSTPROCEDURAL MANAGEMENT**

Contemporary TAVI programs have to streamline post-procedural care and discharge policy, with no distinction between sexes. However, in light of the greater simplification of the TAVI procedure and shortened length of hospital stays, specific attention should be paid to the risk of complications as well as to a tailored pharmacotherapy in female patients.

The increasing clinical experience and advances in device technology have led in many centers to a paradigm shift from general anesthesia to local anesthesia or conscious sedation followed by early discharge (within 48 hours), irrespective of surgical risk. Recent observational data support the benefit of a minimalist approach with reduced procedure time and shorter hospitalization, where next-day discharge will become standard practice, resulting in cost-effective quality care. A reduced risk of nosocomial infections and increased chance of being discharged home is highly appealing in women who are generally older, with less comorbidities, and present later in their disease trajectory to TAVI services.

Notwithstanding, the length of hospitalization after a TAVI procedure is a delicate balance between benefit of early discharge and timely detection of post-procedural complications and should be tailored to individual patient’s medical needs. Advanced age, low BSA, and small vessels make women at higher risk for bleeding and vascular complications in the early period after the procedure. However, careful access-site monitoring and serial hemoglobin measurements within 48 hours allow identification of the majority of vascular access site-related complications before discharge. The FAST TAVI (Feasibility and Safety of Early Discharge After Transfemoral Transcatheter Aortic Valve Implantation) registry demonstrated that prespecified risk criteria based on the rate of 30-day complications could identify patients (48% women) for whom early discharge was safe and effective. Among others, stable hemoglobin values and preserved renal function are pivotal risk evaluation criteria for early discharge and should be attentively examined in women who may have greater prevalence of chronic kidney disease and anemia.

The optimal periprocedural antithrombotic regimen to prevent thrombotic complications and minimize the risk of bleeding is also important. Several randomized trials have investigated the safety and efficacy of different antithrombotic regimens after TAVI (Table 2). However, no specific recommendations have been indicated for women undergoing TAVI procedures. European guidelines currently recommend life-long single antiplatelet therapy or oral anticoagulation in case of patients who have other indications for oral anticoagulation (antiplatelet therapy); dual antiplatelet therapy should be administered only in cases of recent percutaneous coronary intervention. Female sex representation in major randomized trials investigating antithrombotic therapies after TAVI is almost 50% on average; however, no sex-specific subanalyses have been reported to date (Table 2). Observational studies described sex disparities in antiplatelet and antithrombotic management after TAVI with a higher adoption of clopidogrel and a lower use of warfarin because of lower rates of atrial fibrillation. Two large meta-analyses, investigating TAVI outcomes by sex, reported higher rates of major bleeding, vascular complications, and stroke in women, with no impact on survival. Moreover, female sex is an independent predictor of anemia in patients with severe aortic stenosis. The WIN TAVI registry showed that not only is anemia a common finding in elderly women, but also strongly correlates to the long-term prognosis. The sex-based assessment of complications and of pharmacokinetic and pharmacodynamic responses to antithrombotic medications are essential in the periprocedural management of women undergoing TAVI. In case of oral anticoagulation therapy, particular attention has to be paid to hemoglobin values, and an accurate reevaluation of the thrombotic and bleeding risks might be suggested during follow-up. More evidence in the context of large clinical trials investigating the safety and efficacy balance of different antithrombotic strategies according to sex are needed to guide therapeutic decision making in daily clinical practice.
| Study          | Design               | n   | Women, % | Treatment strategy                | Main findings                                                                                                                                                                                                 |
|---------------|----------------------|-----|----------|-----------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Ussia et al95 | Single-center RCT    | 79  | 54.0     | 3 mo DAPT (ASA+C) followed by ASA alone vs ASA | No difference between DAPT vs ASA at 30d (13% vs 15%; $P=0.71$) and 6mo (18% vs 15%; $P=0.85$) in composite of death, MI, stroke, life-threatening bleeding, or urgent conversion to surgery.                                       |
| ARTE96        | Multicenter RCT      | 222 | 36.9     | 3 mo DAPT (ASA+C) vs ASA          | The composite of death, MI, stroke or transient ischemic attack, or major or life-threatening bleeding tended to occur more frequently in the DAPT group (15.3% vs 7.2%; $P=0.065$) within 3 mo after TAVI.                        |
| POPULAR TAVI  | Multicenter RCT      | 665 | 48.7     | 3 mo DAPT (ASA+C) followed by ASA alone vs ASA | 12mo all bleeding: 15.1% with ASA vs 26.6% with DAPT (RR, 0.57 [95% CI, 0.42 to 0.77]; $P=0.001$); 12 mo composite of death from cardiovascular causes, non-procedure-related bleeding, stroke, or MI: 23.0% with ASA vs 31.1% with DAPT (difference, −8.2 percentage points [95% CI for noninferiority, −14.9 to −1.5]; $P=0.001$; RR, 0.74 [95% CI for superiority, 0.57 to 0.95]; $P=0.04$). |
| POPULAR TAVI  | Multicenter RCT      | 313 | 45.4     | 3 mo OAC+C followed by OAC alone vs OAC | 12m all bleeding: 21.7% with OAC vs 34.6% with OAC+C (RR, 0.63 [95% CI, 0.43 to 0.90]; $P=0.01$); 12mo composite of death from cardiovascular causes, non-procedure-related bleeding, stroke, or MI: 31.2% with OAC vs 45.5% with OAC+C (difference, −14.3 percentage points [95% CI for noninferiority, −25.0 to −3.6]; RR, 0.69 [95% CI for superiority, 0.51 to 0.92]). |
| GALILEO99     | Multicenter RCT      | 1644| 49.5     | 3 mo rivaroxaban 10 mg/d+ASA vs 3 mo DAPT (ASA+C) | Primary efficacy outcome composite of death or TE: 9.8 with rivaroxaban and 7.2 with DAPT per 100 person-years (HR, 1.35 [95% CI, 1.01 to 1.81]; $P=0.04$). Primary safety outcome composite of major disabling or life-threatening bleeding: 4.3 with rivaroxaban and 2.8 with DAPT per 100 person-years (HR, 1.50 [95% CI, 0.95 to 2.37]; $P=0.08$). |
| ENVISAGE TAVI AF100 | Multicenter RCT | 1426| 47.5     | Edoxaban 60 mg/d antiplatelet therapy vs VKA antiplatelet therapy | Primary efficacy outcome composite of death from any cause, MI, ischemic stroke, TE, valve thrombosis, or major bleeding: 17.3 with edoxaban and 16.5 with VKA per 100 person-years (HR, 1.05 [95% CI, 0.85 to 1.31]; $P=0.01$ for noninferiority). Major bleeding: 9.7 with edoxaban and 7.0 with VKA per 100 person-years (HR, 1.40 [95% CI, 1.03 to 1.91]; $P=0.03$ for noninferiority). |
| ATLANTIS101   | Multicenter RCT      | 1510| 53.0     | Apixaban 5 mg BID vs single/dual APT or VKA | Primary outcome, time to death, stroke, MI, systemic emboli, intracardiac or valve thrombosis, deep vein thrombosis/pulmonary embolism, or major bleeding for apixaban vs standard of care: 18.4% vs 20.1% (HR, 0.92 [95% CI, 0.73 to 1.16]) (stratum 1: apixaban vs VKA: 21.9% vs 21.9%; stratum 2: 16.9% vs 19.3%; $P$ for interaction =0.57). Primary safety end point of life-threatening, disabling, or major bleeding 8.5% vs 8.5%. |

APT indicates antiplatelet therapy; ARTE, Aspirin vs Aspirin + Clopidogrel Following Transcatheter Aortic Valve Implantation; ASA, aspirin; ATLANTIS, Anti-Thrombotic Strategy After Trans-Aortic Valve Implantation for Aortic Stenosis; C, clopidogrel; DAPT, dual antiplatelet therapy; ENVISAGE-TAVI AF, Edoxaban vs Standard of Care and Their Effects on Clinical Outcomes in Patients Having Undergone Transcatheter Aortic Valve Implantation–Atrial Fibrillation; GALILEO, Global Study Comparing a Rivaroxaban-based Antithrombotic Strategy to an Antiplatelet-based Strategy after Transcatheter Aortic Valve Replacement to Optimize Clinical Outcomes; HR, hazard ratio; MI, myocardial infarction; OAC, oral anticoagulant; POPULAR TAVI, Antiplatelet Therapy for Patients Undergoing Transcatheter Aortic-Valve Implantation; RCT, randomized controlled trial; RR, risk ratio; TAVI, transcatheter aortic valve implantation; TE, thromboembolic events; and VKA, vitamin K antagonist.
CONCLUSIONS
Female patients represent half of the patients undergoing TAVI in clinical studies; however, sex subanalyses are limited, and the impact of sex on outcomes has been poorly investigated. Currently, the unique anatomical characteristics and pathophysiological features of AS in female patients should guide tailored TAVI planning and periprocedural management. Further prospective studies focused around optimization of the therapeutic management of women with severe AS are warranted.

ARTICLE INFORMATION

Affiliations
Department of Cardiac, Thoracic, Vascular Science and Public Health, University of Padova, Italy (O.M., C.F.); Department of Cardiology, Maasstad Hospital, Rotterdam, The Netherlands (V.P.); Department of Advanced Biomedical Sciences, Federico II University of Naples, Italy (A.F., G.E.); Interventional Cardiology Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy (B.B., A.C.); Groupe CardioVasculaire Interventionnel, Clinique Pasteur, Toulouse, France (C.D.B.); Cardiology Department, European Hospital Georges Pompidou, Paris, France (N.K.); Institut Cardiovasculaire Paris Sud,Hopital Privé Jacques CARTIER, Massy, France (F.S.); Klee Cardiovascular Research Group, School of Medicine, Kelee University, Stoke-on-Trent, United Kingdom (M.A.M.); Department of Cardiology, Royal Stoke University Hospital, Stoke-on-Trent, United Kingdom (M.A.M.); Department of Medicine, Thomas Jefferson University, Philadelphia, PA (M.A.M.); Cardiology Department, Rouen University Hospital, Rouen, France (H.E.); Cardiothoracic surgical Department, Ospedale di Circolo, ASST Sette Laghi, Varese, Italy (B.C.); and Division of Interventional Cardiology and Thoracic Department, San Giovanni di Dio e Ruggi, Salerno, Italy (T.A.).

Sources of Funding
This study was partially supported by the Italian Society of Interventional Cardiology (Società Italiana di Cardiologia Interventistica–Gruppo Italiano di Emodinamica), which also supported the publication charge.

Disclosures
Dr Chieffo declares consultant/speaker fees from Abbott Vascular, Abiomed, and Thoracic Department, San Giovanni di Dio e Ruggi, Salerno, Italy (T.A.).

REFERENCES
1. Yadigr S, Johnson CO, Aboyans V, Adebayo OM, Adeyoyin RA, Afardindeh M, Alahmad A, Aliai A, Alipour V, Arabloo J, et al. Global, regional, and national burden of aortic valve disease and degenerative mitral valve diseases, 1990–2017. Circulation. 2020;141:1670–1680. doi: 10.1161/CIRCULATIONAHA.119.043391
2. Garcia M, Mulvagh SL, Merz CN, Buring JE, Manson JE. Cardiovascular management of women with severe AS are warranted. J Am Coll Cardiol. 2016;118:1273–1293. doi: 10.1016/j.jcircisc.2016.07.0547
3. Calabro P, Niccol G, Gragnano F, Grove EL, Vahanian A, Piedbois P, Al Ahmadi G, Cellier P, et al. Sex differences in patients with severe aortic stenosis. J Am Coll Cardiol. 2012;60:1845–1853. doi: 10.1016/j.jacc.2012.06.051
4. Forrest JK, Adams DH, Poppma JJ, Reardon MJ, Deeb GM, Yakubov SJ, Hermiller JB Jr, Huang J, Seldinger KA, Lansky A. Transcatheter aortic valve replacement in women versus men (from the US CoreValve Trials). Ann J Cardiol. 2016;118:396–402. doi: 10.1016/j.amjcard.2016.05.013
5. Humphries KH, Toggweiler S, Rodes-Cabau J, Nombela-Franco L, Dumont E, Wood DA, Wall LJ, Binder RK, Freeman M, Lee MK, et al. Sex differences in mortality after transcatheter aortic valve replacement for severe aortic stenosis. J Am Coll Cardiol. 2012;60:882–886. doi: 10.1016/j.jcct.2012.10.0969
6. Vahanian A, Beyersdorf F, Praz F, Milojicic M, Baldus S, Bauersachs J, Capodanno D, Conrad L, De Bonis M, De Paula R, et al.; ESC/EACTS Scientific Document Group, ESC National Cardiac Societies. 2021 ESC/EACTS Guidelines for the management of valvular heart disease. Eur Heart J. 2022;43:561–632. doi: 10.1093/eurheartj/ehab395
7. Shames S, Gilliam LD. Sex differences in aortic valve calcification. Circ Cardiovasc Imaging. 2013;6:8–10. doi: 10.1016/j.circimaging.2012.02.034
8. Masiero et al Sex Considerations in TAVI
complex nature of discordant severe calcified aortic valve disease grading: new insights from combined Doppler echocardiographic and computed tomographic study. J Am Coll Cardiol. 2013;62:2329–2338. doi: 10.1016/j.jacc.2013.08.1621

24. Tastet L, Kwiecinski J, Pibarot P, Capranzano P, Everest RJ, Newby DE, Shen M, Gueddizzi E, Arsenuel M, Bedard É, et al. Sex-related differences in the extent of myocardial fibrosis in patients with aortic valve stenosis. JACC Cardiovasc Imaging. 2020;13:699–711. doi: 10.1016/j.jcmg.2019.06.014

25. Pighi M, Piazza N, Martucci G, Lachapelle K, Perrault LP, Asgar AW, Lauck S, Webb JG, Poppma JJ, Kim DH, et al. Sex-specific determinants of outcomes after transcatheter aortic valve replacement. Circ Cardiovasc Qual Outcomes. 2019;12:e005363. doi: 10.1161/CIRCOUTCOMES.118.005363

26. O’Connor SA, Morice MC, Gilard M, Leon MB, Webb JG, Dvir D, Rodés-Cabau J, Tamburino C, Capodanno D, D’Ascenzo F, et al. Revisiting sex equality with transcatheter aortic valve replacement outcomes: a collaborative, patient-level meta-analysis of 11,310 patients. J Am Coll Cardiol. 2015;66:221–228. doi: 10.1016/j.jacc.2015.05.024

27. Ad N, Barnett SD, Speir AM. The performance of the EuroSCORE and the Society of Thoracic Surgeons mortality risk score: the gender factor. Interact Cardiovasc Thorac Surg. 2007;6:192–195. doi: 10.1510/icvts.2006.038331

28. Bière L, Launay M, Pinaud F, Hamel JF, Eltchaninoff H, Jung B, Laskar M, Leguerrier A, Gilard M, Furbier A. Influence of sex on mortality and perioperative outcomes in patients undergoing TAVR: insights from the FRANCE 2 registry. J Am Coll Cardiol. 2015;65:755–767. doi: 10.1016/j.jacc.2014.11.044

29. Sannino A, Szerlip M, Harrington K, Schiattarella GG, Grayburn PA. Comparison of baseline characteristics and outcomes in men versus women with aortic stenosis undergoing transcatheter aortic valve implantation. Am J Cardiol. 2018;121:844–849. doi: 10.1016/j.amjcard.2017.12.020

30. Doshi R, Shlofmitz E, Meraj P. Comparison of outcomes and complications of transcatheter aortic valve implantation in women versus men (from the National Inpatient Sample). Am J Cardiol. 2018;121:73–77. doi: 10.1016/j.amjcard.2017.09.015

31. Stelhi D, Dagan M, Zaman S, Koh JQS, Quine E, Gouskova N, Doshi R, Shlofmitz E, Meraj P. Comparison of outcomes and complications of transcatheter aortic valve implantation in women versus men (from the National Inpatient Sample). Am J Cardiol. 2018;121:73–77. doi: 10.1016/j.amjcard.2017.09.015

32. Chandrasekhar J, Morice MC, Aristoy M, Leon MB, Webb JG, Dvir D, Rodés-Cabau J, Tamburino C, Capodanno D, D’Ascenzo F, et al. Gender differences in patients undergoing TAVI: a multicentre study. EuroIntervention. 2013;9:367–372. doi: 10.4244/EIJV9I3A59

33. Buja P, Napodano M, Tamburino C, Petronio AS, Mehilli J, Chandrasekhar J, Sartori S, Lefèvre C, Pontone G, Klugmann S, Bedogni F, Ramondo A, et al. Comparison of variables and 30-day outcomes in women after TAVR: results from the WIN-TAVI registry. Catheter Cardiovasc Interv. 2015;86:221–228. doi: 10.1002/ccd.25634

34. D’Ascenzo F, Gonella A, Moretti C, Omedè P, Salizzoni S, La Torre G, Natale L, Pontone G, Redheuil A, Vliegenthart R, et al. CT and MR imaging prior to transcatheter aortic valve implantation: standardisation of scanning protocols, measurements and reporting—a consensus document by the European Society of Cardiovascular Radiology (ESCR). Eur Radiol. 2020;30:2627–2650. doi: 10.1007/s00330-019-06357-8

35. Buellensfeld L, Stortegcky S, Kulesan B, Glociekler S, Khabtta AA, Nettleship F, Delfine V, Huber C, Eberle B, Meier B, et al. Aortic root dimensions among patients with severe aortic stenosis undergoing transcatheter aortic valve replacement. JACC Cardiovasc Interv. 2015;6:72–83. doi: 10.1016/j.jcin.2012.09.007

36. Dencker D, Taufeld M, Lu KH, Nielsen MB, Kofod KD, Schroeder TV, Sondergaard L, Lønn L, De Backer O. Frequency and effect of access-related vascular injury and subsequent vascular intervention after transcatheter aortic valve replacement. Am J Cardiol. 2016;118:1244–1250. doi: 10.1016/j.amjcard.2016.07.045

37. Mithos CG, Klassens SL, Yucel E. Sex-specific considerations in women with aortic stenosis and outcomes after transcatheter aortic valve replacement. JACC Cardiovasc Interv. 2015;36:72–83. doi: 10.1016/j.jcin.2012.09.007

38. Herrmann HC, Abdel-Wahab M, Attizzani GF, Batchelor W, Bleifelder S, Verdoliva S, Chang Y, Gada H, Gillam L, Guerrero M, et al. Rationale and design of a prospective, randomized, controlled, multicenter study to evaluate the safety and efficacy of transcatheter heart valve replacement in female patients with severe symptomatic aortic stenosis requiring aortic valve intervention (Randomized research in women with Aortic Stenosis [RHEIA] trial). Am Heart J. 2020;228:27–35. doi: 10.1016/j.ahj.2020.06.016

39. Van Wienen MP, Ooms JP, Hennen TW, De Ronde-Tillmans MJ, Goudzaarda JA, Daemen J, De Jaegere PP, Mattace-Raso FU, Van Mieghem NM. Pathways towards lean TAVR. Structural Heart. 2020;4:284–287.

40. Wood DA, Lauck SB, Cairns JA, Humphries KH, Cook R, Welsh R, Leipsic J, Generexus P, Moss R, Rue J, et al. The Vancouver 3M (multidisciplinary, multimodality, but minimalist) clinical pathway facilitates safe next-day discharge home at low-, medium-, and high-volume translesional transcatheter aortic valve replacement centers: the 3M TAVR study. JACC Cardiovasc Interv. 2019;12:459–469. doi: 10.1016/j.jcmi.2018.12.020

41. Otto CM, Kumbhani DJ, Alexander KP, Calhoun JH, Desai MY, Kaul S, Lee JC, Ruiz CE, Vassileva CM. 2017 ACC expert consensus decision pathway for transcatheter aortic valve replacement in the management of adults with aortic stenosis: a report of the American College of Cardiology task force on clinical expert consensus documents. J Am Coll Cardiol. 2017;69:1358–1398. doi: 10.1016/j.jacc.2016.08.005

42. Franco C, Budde RP, Breimerich J, Dacher JN, Loewe C, Wolf T, Natale L, Pontone G, Redheuil A, Vliegenthart R, et al. CT and MR imaging prior to transcatheter aortic valve implantation: standardisation of scanning protocols, measurements and reporting—a consensus document by the European Society of Cardiovascular Radiology (ESCR). Eur Radiol. 2020;30:2627–2650. doi: 10.1007/s00330-019-06357-8
Incidence and sequelae of prosthesis-patient mismatch in transcatheter versus surgical valve replacement in high-risk patients with severe aortic stenosis. J Am Coll Cardiol. 2014;64:1323–1334. doi: 10.1016/j.jacc.2014.06.1195

Rodès-Cabau J, Pibarot P, Suri RM, Kodali S, Thourani VH, Szeto WY, Svensson LG, Dumont E, Xu K, Hahn RT, et al. Impact of aortic annulus size on valve hemodynamics and clinical outcomes after transcatheter and surgical aortic valve replacement: insights from the PARTNER Trial. Circ Cardiovasc Interv. 2014;7:701–711. doi: 10.1161/CIRCINTERVENTIONS.114.010681

Poulin F, Yingchoncharoen T, Wilson WM, Horlick EM, Généreux P, Tuzcu EM, Stewart W, Osten MD, Woo A, Thavendiranathan P. Impact of prosthesis-patient mismatch on left ventricular myocardial mechanics after transcatheter aortic valve replacement. J Am Heart Assoc. 2016;5:e002866. doi: 10.1161/JAHA.115.002866

Thyregod HG, Steinbruchel DA, Ihllemann N, Ngo TA, Nissen H, Kjeldsen BJ, Chang Y, Hansen PB, Olsen PS, Sonderegger LA. No clinical effect of prosthesis-patient mismatch after transcatheter versus surgical aortic valve replacement in intermediate- and low-risk patients with severe aortic valve stenosis at mid-term follow-up: an analysis from the NOTION trial. Eur J Cardiothorac Surg. 2016;50:721–728. doi: 10.1093/ejcts/ezw095

Akodad M, Sellers S, Gulin GS, Tizimas G, Landes U, Chafitz AG, Chuang A, Meier D, Leipisc J, Blanke P, et al. Leaflet and neoskirt height in transcatheter heart valves: implications for repeat procedures and coronary access. JACC Cardiovasc Interv. 2021;14:2298–2310. doi: 10.1016/j.jcin.2020.11.034

Ochiai T, Oakley L, Sekhon N, Komatsu I, Flint N, Kaelwek D, Yoon SH, Raschpichler M, Patel V, Tiwana R, et al. Risk of coronary obstruction due to sinus sequestration in redo transcatheter aortic valve replacement. JACC Cardiovasc Interv. 2020;13:2617–2627. doi: 10.1016/j.jcin.2020.09.022

Nai Fovino L, Scotti A, Massuasi M, Fabris T, Cardaioli F, Rodinò G, Matsuda Y, Frigo F, Fracaro C, Taratanti G. Incidence and feasibility of coronary access after transcatheter aortic valve replacement. Catheter Cardiovasc Interv. 2020;96:ES53–ES54. doi: 10.1002/ccd.28720

Kotronias RA, Bray JJH, Rajasundaram S, Vincent F, Delhaye C, Scarsini R, Marin F, Terentes-Printzios D, Halcox JP, Mamas MA, et al. Ultrasound- versus fluoroscopy-guided strategy for transapical transcatheter aortic valve replacement access: a systematic review and meta-analysis. Circ Cardiovasc Interv. 2021;14:e010742. doi: 10.1161/CIRCINTERVENTIONS.121.001681

Di Mario C, Goodwin M, Ristalli F, Ravani M, Meucci F, Stolcova M, Chandrasekhar J, Hibbert B, Ruel M, Lam BK, Labinaz M, Glover J. Pathophysiological factors associated with left ventricular perforation in transcatheter aortic valve implantation by transfemoral approach. J Heart Valve Dis. 2017;26:430–436.

Rezaz A, Basavaraia JS, Labit A, Takagi K, Hasegawa T, Figini F, Cioni M, Franco A, Montorlano M, Chieffo A, et al. Incidence, management, and outcomes of cardiac tamponade during transcatheter aortic valve implantation: a single-center study. JACC Cardiovasc Interv. 2012;5:1264–1272. doi: 10.1016/j.jcin.2012.08.012

Tamborino C, Alba A, Cohen MG, Kapardis SA, Kodali S, Tamburino C, Barbanti M, Chakravarty T, Jilaihawi H, et al. Predictive factors, management, and clinical outcomes of coronary obstruction following transcatheter aortic valve implantation: insights from a large multicenter registry. J Am Coll Cardiol. 2013;62:1552–1562. doi: 10.1016/j.jacc.2013.07.040

Westermann D, Ludwing S, Kalbacher D, Spink C, Linder M, Shadra OD, Nikorowitsch J, Waldschmidt L, Denol T, Voigtlander L, et al. Prevention of coronary obstruction in patients at risk undergoing transcatheter aortic valve implantation: the Hamburg BAVILLA experience. Clin Res Cardiol. 2021;110:1900–1911. doi: 10.1007/s00392-021-01881-4

Khan JM, Greenbaum AB, Babbalaro VC, Dvir D, Reisman M, McCabe JM, Satler L, Waksman R, Eng MH, Paone G, et al. BAVILLA trial: one-year outcomes of transcatheter electro surgical leaflet laceration to prevent TAVR coronary obstruction. Circ Cardiovasc Interv. 2021;14:e010238. doi: 10.1161/CIRCINTERVENTIONS.120.010238

Poschner T, Werner P, Kocher A, Laufer G, Musuemei F, Andreas M, Russo M. The JenaValve pericardial transcatheter aortic valve replacement system to treat aortic valve disease. Future Cardiovasc. 2021;18:101–107. doi: 10.4244/FICV.2021.18.015

Abdel-Wahab M, Zahn R, Horack M, Gercenius U, Schuler G, Sievert E, Eggebrecht H, Senges J, Richard T, German transcatheter aortic valve interventions registry investigators. Aortic regurgitation after transcatheter aortic valve implantation: incidence and early outcome. Results from the German transcatheter aortic valve interventions registry. Heart. 2011;97:899–906. doi: 10.1136/hrt.2010.217158

Barbanti M, Yang TH, Roddis Cabaju J, Tamburino C, Wood DA, Jilaihawi H, Blanke P, Makkar RR, Labit A, Colombo A, et al. Anatomical and procedural features associated with aortic root rupture during balloon-expandable transcatheter aortic valve replacement. Circulation. 2013;128:244–253. doi: 10.1161/CIRCULATIONAHA.113.002947

Mas-Peiro S, Weiler H, Papadopoulos N, Zehner AM, Fichtscherer S, Vasa-Nicotera M. Post-procedural ratio of hemodynami cally assessed aortic regurgitation index as a marker for the need for corrective measures during transcatheter valve replacement: a first confirmatory study in patients receiving a new generation transcatheter self-expandable prosthesis. Catheter Cardiovasc Interv. 2019;93:532–537. doi: 10.1002/ccd.27847

Tarantini G, Mojoli M, Purita P, Papadoni M, D’Onofrio A, Frigo A, Covolo E, Facchin M, Isabella G, Gerosa G, et al. Unraveling the (ante) factor of increased pacemaker rate with the Edwards SAPIEN 3 valve. EuroIntervention. 2015;11:343–350. doi: 10.4244/EIJY14M11_06

Jilaihawi H, Zhao Z, Du R, Staniloae C, Saric M, Neuburger PJ. Component pacemaker following repositionable self-expanding transcatheter aortic valve implantation. JACC Cardiovasc Interv. 2019;12:1796–1807. doi: 10.1016/j.jcin.2019.05.056
80. Tarantini G, Fabris T, Nai FL. TAVR-in-TAVR and coronary access: importance of preprocedural planning. EuroIntervention. 2020;16:e129–e132. doi: 10.4244/EUJ-19-01094

81. Tarantini G, Nai Fovino L, Le Prince P, Darremont O, Urena M, Bartorelli AL, Vincent F, Hovorka T, Alcalá Navarro Y, Dumontel N, et al. Coronary access and percutaneous coronary intervention up to 5 years after transcatheter aortic valve implantation with a balloon-expandable valve. Circ Cardiovasc Interv. 2020;13:e008972. doi: 10.1161/CIRCINTERVENTIONS.120.008972

82. Nai Fovino L, Scotti A, Massussi M, Cardaioli F, Rodinò G, Matsuda Y, Pavli A, Masiero G, Napodano M, Fraccaro C, et al. Coronary angiography after transcatheter aortic valve replacement (TAVR) to evaluate the risk of coronary access impairment after TAVR-in-TAVR. J Am Heart Assoc. 2020;9:e016446. doi: 10.1161/JAHA.120.016446

83. Tarantini G, Nai Fovino L. Lifetime strategy of patients with aortic stenosis: the first cut is the deepest. JACC Cardiovasc Interv. 2021;14:1727–1730. doi: 10.1016/j.jcin.2021.06.029

84. Tarantini G, Nai FL. Coronary access and TAVR-in-TAVR: don’t put off until tomorrow what you can do today. JACC Cardiovasc Interv. 2020;13:2539–2541. doi: 10.1016/j.jcin.2020.08.065

85. Attizzani GF, Alkhalil A, Padalia B, Tam CC, Lopes JP, Fares A, Bezerra JG, Medallion B, Park S, Deo S, et al. Comparison of Outcomes of transfemoral transcatheter aortic valve implantation using a minimally invasive versus conventional strategy. Am J Cardiol. 2015;116:1731–1736. doi: 10.1016/j.amjcard.2015.08.044

86. Babaliaros V, Devireddy C, Lerakis S, Leonardi R, Iturra SA, Mavromatis J, Pavei A, Leshnower BG, Guyton RA, Kanitkar M, Keegan P, et al. Comparison of Outcomes of hospital stay for patients undergoing minimalist transcatheter aortic valve replacement. Catheter Cardiovasc Interv. 2018;91:345–353. doi: 10.1002/jc.27230

87. Alkhalil A, Lamba H, Deo S, Bezerra HG, Patel SM, Simon DI, Costa MA, Davis AC, Attizzani GF. Safety of shorter length catheterization laboratory (minimalist approach) versus hybrid operating room (standard approach): outcomes and cost analysis. JACC Cardiovasc Interv. 2014;7:898–904. doi: 10.1016/j.jcin.2014.04.005

88. Babaliaros V, Devireddy C, Lerakis S, Leonard R, Iturra SA, Mavromatis K, Leshnower BG, Guyton RA, Kanitkar M, Keegan P, et al. Comparison of Outcomes of transfemoral transcatheter aortic valve replacement performed in the catheterization laboratory (minimalist approach) versus hybrid operating room (standard approach): outcomes and cost analysis. JACC Cardiovasc Interv. 2014;7:898–904. doi: 10.1016/j.jcin.2014.04.005

89. Alkhalil A, Lamba H, Deo S, Bezerra HG, Patel SM, Simon DI, Costa MA, Davis AC, Attizzani GF. Safety of shorter length catheterization laboratory (minimalist approach) versus hybrid operating room (standard approach): outcomes and cost analysis. JACC Cardiovasc Interv. 2014;7:898–904. doi: 10.1016/j.jcin.2014.04.005

90. Leon MB, Smith CR, Mack MJ, Makkar RR, Svensson LG, Kodali SK, Thourani VH, Tuzcu EM, Miller DC, Herrmann HC, et al. Transcatheter or surgical aortic-valve replacement in intermediate-risk patients. N Engl J Med. 2016;374:1609–1620. doi: 10.1056/NEJMoa1514616

91. Reardon MJ, Van Mieghem NM, Popma JJ, Kleiman NS, Serruys PW, Moules J, de Winter RJ, Kapadia SR, Malaisrie SC, Cohen DJ, Pibarot P, et al. Transcatheter aortic-valve replacement in intermediate-risk patients. N Engl J Med. 2017;376:1321–1331. doi: 10.1056/NEJMoa1700456

92. Mack MJ, Leon MB, Thourani VH, Makkar RR, Kodali SK, Russo M, Kapadia SR, Malaisrie SC, Cohen DJ, Pibarot P, et al. Transcatheter aortic-valve replacement with a balloon-expandable valve in low-risk patients. N Engl J Med. 2019;380:1695–1705.

93. Calabò P, Gragnano F, Niccoli G, Marcucci R, Zimarrino M, Spaccarotella C, Renda G, Patti G, Andò G, Moscarella E, et al. Antithrombotic therapy in patients undergoing transcatheter intervention for structural heart disease. Circulation. 2021;144:1323–1343. doi: 10.1161/CIRCULATIONAHA.121.054305

94. Capodanno D, Collet JP, Dangas G, Montalescot G, Ten Berg JM, Windecker S, Angiolillo DJ. Antithrombotic therapy after transcatheter aortic valve replacement. JACC Cardiovasc Interv. 2021;14:1688–1703. doi: 10.1016/j.jcin.2021.06.020

95. Ussia GP, Scarabelli M, Mule M, Barbanti M, Sarkar K, Cammallleri V, Immé S, Aruta P, Pistritto AM, Gulino S, et al. Dual antiplatelet therapy versus aspirin alone in patients undergoing transcatheter aortic valve implantation. Am J Cardiol. 2011;108:1772–1776. doi: 10.1016/j.amjcard.2011.07.049

96. Rodés-Cabau J, Masson JB, Welsh RC, Garcia Del Blanco C, Pelletier M, Webb JG, Al-Coofi F, Généreux P, Maluenda G, Thoenes M, et al. Aspirin versus aspirin plus clopidogrel as antithrombotic treatment following transcatheter aortic valve replacement with a balloon-expandable valve: the ARTE (Aspirin Versus Aspirin+Clopidogrel Following Transcatheter Aortic Valve Implantation) randomized clinical trial. JACC Cardiovasc Interv. 2017;10:1357–1365. doi: 10.1016/j.jcin.2017.04.014

97. Brouwer J, Nijhuis VJ, Delewi R, Heramnides RS, Holvot W, Dubois CLF, Frambach P, De Bruyne B, van Houwelingen GK, Van Der Heyden JAS, et al. Aspirin with or without clopidogrel after transcatheter aortic valve implantation. N Engl J Med. 2020;383:1447–1457. doi: 10.1056/NEJMoa1911512

98. Nijhuis VJ, Brouwer J, Delewi R, Heramnides RS, Holvot W, Dubois CLF, Frambach P, De Bruyne B, van Houwelingen GK, Van Der Heyden JAS, et al. Anticoagulation with or without clopidogrel after transcatheter aortic valve implantation. N Engl J Med. 2020;382:1696–1707. doi: 10.1056/NEJMoa1917815

99. Ganges GD, Tijssen JGP, Wöhrlie J, Serruys PW, Lidgard M, Möllmann H, Makkar RR, Herrmann HC, Giustino G, Baldus S, et al. A controlled trial of rivaroxaban after transcatheter aortic valve replacement. N Engl J Med. 2020;382:120–129. doi: 10.1056/NEJMoa1911425

100. Van Mieghem NM, Verduin M, Hengstenberg C, Möllmann H, Mehran R, López-Otero D, Nombela-Franco L, Moreno R, Nordbeck P, Thiele H, et al. Edoxaban versus vitamin K antagonist for atrial fibrillation after TAVR. N Engl J Med. 2021;385:2150–2160. doi: 10.1056/NEJMoa2111016

101. Collet J-P. Oral anti-Xa anticoagulation after transcatheter aortic valve implantation for aortic stenosis: the randomized ATLANTIS trial Presented at: ACC 2021. May 15, 2021.